MAGENTA THERAPEU(MGTA) - 2025 Q3 - Quarterly Report

Financial Performance - Total revenues for the three months ended September 30, 2025, were $396,000, a decrease from $2,172,000 in the same period of 2024[18] - The net loss for the three months ended September 30, 2025, was $36,765,000, compared to a net loss of $25,174,000 for the same period in 2024, representing a 46% increase in losses[18] - For the nine months ended September 30, 2025, the net loss was $97,905,000, compared to a net loss of $56,529,000 for the same period in 2024, representing an increase of 73%[24] - The Company reported net losses of $97.9 million and $56.5 million for the nine months ended September 30, 2025 and 2024, respectively, with an accumulated deficit of $272.3 million as of September 30, 2025[49] - The Company reported total revenues of $396,000 for the three months ended September 30, 2025, compared to $2,172,000 for the same period in 2024, representing an 81.8% decrease[60] Research and Development Expenses - Research and development expenses for the three months ended September 30, 2025, were $32,489,000, compared to $25,544,000 for the same period in 2024, reflecting a 27% increase[18] - The company reported stock-based compensation expense of $16,815,000 for the nine months ended September 30, 2025, compared to $8,976,000 in 2024, reflecting an increase of 87%[24] - The total stock-based compensation expense for the nine months ended September 30, 2025, was $16.8 million, compared to $9.0 million for the same period in 2024, reflecting an increase of 87%[96] - The Company has approximately $87.9 million of remaining unamortized domestic R&D expenditures as of December 31, 2024, which represents about $21.7 million of its gross deferred tax assets[55] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $55,984,000, up from $22,792,000 as of December 31, 2024[16] - Total assets increased to $577,445,000 as of September 30, 2025, compared to $374,008,000 as of December 31, 2024[16] - Total cash, cash equivalents, and restricted cash at the end of the period was $56,151,000, compared to $33,900,000 at the end of September 30, 2024, showing a 65% increase[24] - The Company’s cash equivalents totaled $54,994,000 as of September 30, 2025, compared to $21,946,000 as of December 31, 2024, reflecting a significant increase[61] - Total marketable securities amounted to $499,503,000 as of September 30, 2025, up from $334,177,000 as of December 31, 2024, indicating a growth of 49.5%[61] Shareholder Equity and Stock - Total stockholders' equity as of September 30, 2025, was $546,454,000, an increase from $352,477,000 as of December 31, 2024[16] - The weighted-average number of shares of common stock outstanding for the three months ended September 30, 2025, was 37,794,080, compared to 34,236,720 for the same period in 2024[18] - Following the reverse merger, the company issued 11,021,248 shares of common stock to former stockholders of Dianthus, increasing total shares outstanding to 14,817,696[30] - The company had a total of 42,854,563 shares of common stock issued and outstanding as of September 30, 2025[79] - The company had 9,740,757 shares of common stock reserved for future issuance as of September 30, 2025, down from 11,187,790 shares as of December 31, 2024[80] Business Combinations and Financing Activities - The company completed a business combination with Former Dianthus on September 11, 2023, which resulted in Former Dianthus becoming a wholly owned subsidiary[13] - The company completed a public offering that generated proceeds of $272,268,000, significantly contributing to financing activities[24] - On September 11, 2025, the Company completed an underwritten offering, raising gross proceeds of $288.4 million from the sale of 7,627,879 shares at a public offering price of $33.00 per share[38] - The Company raised approximately $72.0 million through a pre-closing financing, issuing 2,873,988 shares of common stock and 210,320 pre-funded warrants at a price of approximately $23.34 per share[35] - In a private placement on January 24, 2024, the Company sold 14,500,500 shares at $12.00 per share and pre-funded warrants for an aggregate of approximately $230 million[36] Operational Costs - The company reported total operating expenses of $40,684,000 for the three months ended September 30, 2025, compared to $32,072,000 for the same period in 2024, marking a 27% increase[18] - The Company’s total general and administrative expenses for the three months ended September 30, 2025, were $8,195,000, an increase of 25.5% from $6,528,000 in the same period of 2024[60] - Cash used in operating activities for the nine months ended September 30, 2025, was $82,077,000, up from $50,736,000 in the prior year, indicating a 62% increase in cash outflow[24] Strategic Focus and Risks - The company has been focusing on research and development for next-generation therapies to treat severe autoimmune diseases, indicating a strategic emphasis on innovation[26] - The Company is subject to risks common to early-stage biotechnology companies, including product development uncertainty and reliance on outside capital for operations[42] - The Company expects significant recurring losses and relies on outside capital to fund operations for the foreseeable future, with increasing research and development costs anticipated[49] Licensing and Collaboration Agreements - The company recognized license revenue of $1.8 million associated with the Tenacia License Agreement for the nine months ended September 30, 2025[111] - The Company is obligated to pay Alloy Therapeutics up to $1.8 million for development milestones and $11.0 million for commercial milestones related to products developed with Alloy antibodies[114] - Under the collaborative research agreement with IONTAS, the Company is obligated to make payments of up to £3.1 million (approximately $4.2 million) for development milestones and £2.3 million (approximately $3.1 million) for commercial milestones[116] - The Company entered into a License and Collaboration Agreement with Nanjing Leads Biolabs Co. Ltd., with potential payments of up to $38.0 million, including $30.0 million in upfront and near-term milestone payments[124]